Description

Anditixafortide (Pentixather) is an endoradiotherapeutic vector. Anditixafortide is a CXCR4-targeting peptide derivative[1].—–C60H79IN14O14—-[1]Nicolas Lepareur, et al. Clinical Advances and Perspectives in Targeted Radionuclide Therapy. Pharmaceutics. 223, 15, 6.|[2]Ken Herrmann, et al. First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease. J Nucl Med. 2016, 57, 2.–1821136-83-7–1347.26—-O=C([C@@H](NC([C@H](N(C([C@H](NC(CNC1=O)=O)CC2=CC(I)=C(C=C2)O)=O)C)CCCNC(C3=CC=C(C=C3)CNC(CN4CCN(CCN(CCN(CC4)CC(O)=O)CC(O)=O)CC(O)=O)=O)=O)=O)CCCNC(N)=N)N[C@H]1CC5=CC6=C(C=CC=C6)C=C5–Cancer–10 mM in DMSO–Others—-Others–Peptides